Clinical Trials Browser

Phase 2 × Recurrence × anlotinib × Clear all

NCT04996758 2024-12-12

Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)

Phase 2 Completed

Nasopharyngeal Carcinoma, Recurrence

NCT03591666 2018-07-19

A Study of Anlotinib in Recurrent/Metastatic Head and Neck Adenocarcinomas

Phase 2 Unknown

Adenocarcinoma, Recurrence